Search Results
May 28, 2026, 09:15 ET Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
therapeutically actionable targets. The program is intended to support precision medicine strategies and accelerate the development of differentiated CNS therapeutics.In a flagship program under the collaboration, BioSymetrics and Brainstorm Therapeutics, together with Dr. Calum MacRae at Brigham
More news about: Lunai Bioworks Inc.
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
2026 total net product revenue guidance of $4.9–$5.3 billion and is advancing more than 25 clinical programs across rare disease, cardiometabolic, and CNS indications.Beam Therapeutics Inc. (NASDAQ: BEAM) on May 18, 2026 presented updated
More news about: USA News Group
May 28, 2026, 04:00 ET Cohen & Steers Real Assets Strategies Now Available in South Africa
LONDON, May 28, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that three funds of the Cohen & Steers SICAV – the Global Listed Infrastructure Fund, the Global Real Estate Securities Fund, and
More news about: Cohen & Steers, Inc.
May 27, 2026, 18:18 ET U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
included a total of 84 patients who were part of the trial. Of these, 33 patients with no CNS involvement received DECNUPAZ as a frontline treatment and 51 had relapsed or refractory disease without evidence of active CNS disease. Eleven patients in the frontline treatment group had prior or concurrent cancer
More news about: AbbVie
May 27, 2026, 18:04 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers REIT and Preferred Income Fund, Inc.
May 27, 2026, 18:02 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Closed-End Opportunity Fund, Inc.
May 27, 2026, 18:01 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Quality Income Realty Fund, Inc.
May 27, 2026, 17:58 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Total Return Realty Fund, Inc.
May 27, 2026, 17:47 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers Select Utility Fund, Inc.
May 27, 2026, 09:45 ET CenExel highlights industry-leading capabilities amid growing FDA momentum advancing psychedelic clinical research
studies.CenExel's capabilities supporting psychedelic clinical trials include:Extensive experience conducting complex CNS and behavioral health studiesAccess to specialized patient populations across multiple indicationsHighly trained investigators and
More news about: CenExel Clinical Research
May 27, 2026, 09:31 ET Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced that it
More news about: Sensorium Therapeutics
May 27, 2026, 08:00 ET Verge Labs Launches as a Frontier AI Lab for Human Disease Biology
Formerly Verge Genomics, the company is training frontier models on one of the largest proprietary multimodal CNS patient datasets ever assembled – more than 12,000 human brain samples – to predict how individual patients will respond to therapy. Four senior hires join from Altos Labs, Calico,
More news about: Verge Labs
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
May 27, 2026, 06:30 ET Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
May 27, 2026, 03:00 ET ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.The Company headquarters are in Valencia, Spain.For more information on ArthemiR™, please visit
More news about: ARTHEx Biotech
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.
More news about: Hackensack Meridian John Theurer Cancer Center
May 26, 2026, 12:30 ET ENA Honors Nycole Oliver With Prestigious 2026 Judith C. Kelleher Award
of New YorkLifetime Achievement Award:Beth Manganaro, RN, CEN, TCRN, of New JerseyValerie Brumfield, MSN, RN, CNS, CEN, CCRN, of TexasMedia Award:Onslow Memorial Hospital Emergency Department and Marketing Team, North CarolinaJaqueline
More news about: Emergency Nurses Association
May 26, 2026, 09:00 ET TOBY Receives FDA Breakthrough Device Designation for Its Urine-Based Alzheimer's Disease Diagnostic Test
evaluated."The Alzheimer's designation is TOBY's third FDA Breakthrough Device Designation, expanding its portfolio across oncology and central nervous system (CNS) disease and reinforcing the company's broader platform strategy around urine-based molecular diagnostics.The FDA's Breakthrough Devices Program
More news about: TOBY, Inc.
May 26, 2026, 08:00 ET 28bio Launches CNS-3D Alzheimer's Model to Predict Therapeutic Efficacy
therapies."The CNS-3D Induced Alzheimer's Model builds on our expertise in New Approach Methods for neurological drug development," said Stuart Gibb, Head of Business Development at 28bio. "The CNS-3D Induced Alzheimer's Model will begin shipping globally in Q3'26 or can be accessed through CNS Services."The
More news about: 28bio
May 26, 2026, 07:30 ET Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
study, rates of these central nervous system (CNS) AEs were less than or equal to 5% each.Opakalim's tolerability profile is markedly differentiated from that of other investigational Kv7 activators reporting double-digit rates of CNS AEs in OLE studies.On
More news about: Biohaven Ltd.
May 26, 2026, 04:00 ET Boeing Saudi Arabia and GACA launch AAM Airspace and Operational Feasibility Analysis with support from SkyGrid, and KAUST
Analysis with support from SkyGrid & KAUSTThe Feasibility Analysis will evaluate AAM routes and cooperative airspace areas, CNS and other infrastructure, and associated vertiports and airports to demonstrate the viability of safe and sustainable AAM operations for both piloted
More news about: SkyGrid
May 22, 2026, 08:15 ET Psilera, Inc. to Present at Upcoming Industry and Investor Conferences
Oppenheimer CNS and Neuro-Muscular SummitDate: June 10, 2026Location: Miami, FLPsilera Representative:
More news about: Psilera, Inc.
May 22, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Brings the Power of Its Integrated Network to ASCO 2026
immune landscape of glioblastoma (Abstract 2006, oral session) — a continuation of PICI's long-standing commitment to neoantigen-based strategies in CNS cancers.Massachusetts General Hospital (Marcela Maus, MD, PhD): Rituximab pre-conditioning in the Phase 1 INCIPIENT trial of CARv3-TEAM-E
More news about: Parker Institute for Cancer Immunotherapy
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors.Monday,
More news about: AbbVie
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.